Rank
714
Alexion Pharmaceuticals
- Previous Rank815
- Revenues ($M)3084
- Revenue Percent Change18.4
- Profits ($M)399
- Profits Percent Change176.3
- Assets ($M)13253
- Employees3121
- Market Value — as of March 31, 2017 ($M)27297
Company Info
| CEO | Ludwig N. Hantson |
| CEO Title | Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New Haven, CT |
| Website | www.alexion.com |
| Years on Fortune 500 List | - |
| Employees | 3,121 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $3,084 |
| Profits ($M) | $399 |
| Assets ($M) | $13,253 |
| Total Stockholder Equity ($M) | $8,694 |
| Market Value — as of March 31, 2017 ($M) | $27,297 |
Profit Ratios
| Profit as % of Revenues | 12.9% |
| Profits as % of Assets | 3% |
| Profits as % of Stockholder Equity | 4.6% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 176 |
| EPS % Change (from 2015) | 162.7% |
| EPS % Change (5 year annual rate) | 14.1% |
| EPS % Change (10 year annual rate) | - |
Total Return
| Total Return to Investors (2016) | -35.9% |
| Total Return to Investors (5 year, annualized) | 11.3% |
| Total Return to Investors (10 year, annualized) | 28.3% |